By Liz White, UT editor
Strathclyde, Scotland-AorTech International plc, a developer and licensor of medical devices and biomaterials, has signed a non-exclusive licence and material supply agreement with Allium Medical Inc., a Delaware-based company, for the purchase and use of AorTech's Elast-Eon? bio-material in the field of non-vascular stents.
Under the agreement, AorTech said, it will receive annual minimum revenues and royalties on the sales of Allium products manufactured from AorTech materials.
"The completion of this agreement with Allium Medical is important to AorTech for its role in opening the urological market to the use of Elast-Eon," commented Frank Maguire, AorTech's ceo, in a company announcement.
"We have been working closely with the product design engineers at Allium on the development of a specific formulation ideally suited for urological implant use," Maguire added.
Other on-going work for AorTech with other partners covers various Elast-Eon material classes, being qualified for use in orthopaedic, cardiology and other long-term implants, he concluded.
AorTech International, based in Strathclyde, owns AorTech Biomaterials of Melbourne, Australia, a company set up in July 1997 to commercialise a range of medical grade polyurethanes for medical implants developed by the Commonwealth Scientific and Industrial Research Organisation (CSIRO).
AorTech's Elast-Eon materials are patented, high silicone content, polyurethane copolymers which "exhibit unparalleled biological and mechanical performance," the firm says.
Privately owned company Allium Inc., was founded by Prof Daniel Yachia, an acknowledged urologist and international authority on Urinary System Stenting. The company owns an R&D subsidiary, Allium Ltd, in Israel.